Cost Effectiveness of Pertussis Vaccination in Adults

Background Prior economic analyses have reached disparate conclusions about whether vaccinating adults against pertussis would be cost effective. Newly available data on pertussis incidence were used to evaluate the cost effectiveness of one-time adult vaccination and adult vaccination with decennia...

Full description

Saved in:
Bibliographic Details
Published in:American journal of preventive medicine 2007-03, Vol.32 (3), p.186-193.e2
Main Authors: Lee, Grace M., MD, MPH, Murphy, Trudy V., MD, Lett, Susan, MD, MPH, Cortese, Margaret M., MD, Kretsinger, Katrina, MD, MA, Schauer, Stephanie, PhD, Lieu, Tracy A., MD, MPH
Format: Article
Language:English
Subjects:
Adult
Bordetella pertussis - immunology
Cost-Benefit Analysis
Female
Humans
Incidence
Internal Medicine
Male
Markov Chains
Middle Aged
Pertussis Vaccine - economics
Preventive Medicine - economics
United States
Whooping Cough - economics
Whooping Cough - microbiology
Whooping Cough - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Prior economic analyses have reached disparate conclusions about whether vaccinating adults against pertussis would be cost effective. Newly available data on pertussis incidence were used to evaluate the cost effectiveness of one-time adult vaccination and adult vaccination with decennial boosters. Methods A Markov model was used to calculate the health benefits, risks, costs, and cost effectiveness of the following strategies: (1) no adult pertussis vaccination, (2) one-time adult vaccination at 20–64 years, and (3) adult vaccination with decennial boosters. The impact of the severity of pertussis illness, vaccine adverse events, and herd immunity on model outcomes were also examined. Results At a disease incidence of 360 per 100,000, the one-time adult vaccination strategy would prevent 2.8 million cases, and the decennial vaccination strategy would prevent 8.3 million cases. As disease incidence varied from 10 to 500 per 100,000, the one-time adult vaccination strategy was projected to prevent 79,000 to 3.8 million adult pertussis cases, while the decennial vaccination program would prevent 239,000 to 11.4 million cases. A one-time adult vaccination strategy would result in 106 million people vaccinated, or approximately 64% of the adult cohort, for a total program cost of $2.1 billion, while a decennial vaccination strategy would cost $6.7 billion. The one-time and decennial booster vaccination strategies result in cost-effectiveness ratios of
ISSN:0749-3797
1873-2607
DOI:10.1016/j.amepre.2006.10.016